Tokyo Tape
Sign in
← Oncolys BioPharma

Annual report

4588.TEDINET S100PNBS
Period2018-01-01 → 2018-12-31
Filed2022-11-17
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed

Amends S100FIR2.

Key figures · 78
MetricValuePeriodScopeSource row
Revenue¥169m2018-01-01 → 2018-12-31StandaloneNet sales
Revenue¥229m2017-01-01 → 2017-12-31StandaloneNet sales
Revenue¥178m2016-01-01 → 2016-12-31dStandaloneNet sales (5-year summary)
Revenue¥121m2015-01-01 → 2015-12-31dStandaloneNet sales (5-year summary)
Revenue¥29m2014-01-01 → 2014-12-31dStandaloneNet sales (5-year summary)
Operating income−¥1.2bn2018-01-01 → 2018-12-31StandaloneOperating income
Operating income−¥1.1bn2017-01-01 → 2017-12-31StandaloneOperating income
Ordinary income−¥1.2bn2018-01-01 → 2018-12-31StandaloneOrdinary income
Ordinary income−¥1.1bn2017-01-01 → 2017-12-31StandaloneOrdinary income
Ordinary income−¥864m2016-01-01 → 2016-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥855m2015-01-01 → 2015-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥726m2014-01-01 → 2014-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.2bn2018-01-01 → 2018-12-31StandaloneIncome before income taxes
Profit before tax−¥1.1bn2017-01-01 → 2017-12-31StandaloneIncome before income taxes
Net income−¥1.2bn2018-01-01 → 2018-12-31StandaloneProfit loss
Net income−¥1.1bn2017-01-01 → 2017-12-31StandaloneProfit loss
Net income−¥931m2016-01-01 → 2016-12-31dStandaloneNet income loss (5-year summary)
Net income−¥857m2015-01-01 → 2015-12-31dStandaloneNet income loss (5-year summary)
Net income−¥739m2014-01-01 → 2014-12-31dStandaloneNet income loss (5-year summary)
Total assets¥3.4bnat 2018-12-31StandaloneAssets
Total assets¥3.5bnat 2017-12-31StandaloneAssets
Total assets¥3.1bnat 2016-12-31dStandaloneTotal assets (5-year summary)
Total assets¥4.0bnat 2015-12-31dStandaloneTotal assets (5-year summary)
Total assets¥5.0bnat 2014-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥529mat 2018-12-31StandaloneLiabilities
Total liabilities¥594mat 2017-12-31StandaloneLiabilities
Net assets / equity¥2.9bnat 2018-12-31StandaloneNet assets
Net assets / equity¥2.9bnat 2017-12-31StandaloneNet assets
Net assets / equity¥2.6bnat 2016-12-31dStandaloneNet assets
Net assets / equity¥3.5bnat 2015-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥4.4bnat 2014-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥2.5bnat 2018-12-31StandaloneCash and deposits
Cash and deposits¥2.9bnat 2017-12-31StandaloneCash and deposits
Cash & equivalents¥2.2bnat 2018-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.9bnat 2017-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.4bnat 2016-12-31dStandaloneCash and cash equivalents
Cash & equivalents¥2.1bnat 2015-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥1.2bnat 2014-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥1.2bn2018-01-01 → 2018-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.1bn2017-01-01 → 2017-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥903m2016-01-01 → 2016-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥756m2015-01-01 → 2015-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥814m2014-01-01 → 2014-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow¥342m2018-01-01 → 2018-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥132m2017-01-01 → 2017-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥257m2016-01-01 → 2016-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥1.8bn2015-01-01 → 2015-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥3.4bn2014-01-01 → 2014-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥1.1bn2018-01-01 → 2018-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.5bn2017-01-01 → 2017-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥6m2016-01-01 → 2016-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥120m2015-01-01 → 2015-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥233,0002014-01-01 → 2014-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-104.552018-01-01 → 2018-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-106.232017-01-01 → 2017-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-101.182016-01-01 → 2016-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-93.352015-01-01 → 2015-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-80.552014-01-01 → 2014-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥216.61at 2018-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥263.54at 2017-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥283.43at 2016-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥381.27at 2015-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥476.03at 2014-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio84.3%at 2018-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio82.9%at 2017-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio82.7%at 2016-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio87.2%at 2015-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio87.2%at 2014-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued13,346,000at 2018-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued11,086,000at 2017-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued9,234,600at 2016-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued9,183,800at 2015-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued9,183,200at 2014-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees30at 2018-12-31StandaloneNumber of employees
Employees29at 2017-12-31StandaloneNumber of employees
Employees30at 2016-12-31dStandaloneNumber of employees
Employees29at 2015-12-31dStandaloneNumber of employees
Employees28at 2014-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 22
SegmentItemPeriodValue
Reconciling Itemsreconcilingdepreciation2018-01-01 → 2018-12-31¥2m
Reconciling Itemsreconcilingsegment profit2018-01-01 → 2018-12-31−¥593m
Diagnostic Divisionreportable segmentrevenue2018-01-01 → 2018-12-31¥16m
Diagnostic Divisionreportable segmentrevenue external2018-01-01 → 2018-12-31¥16m
Diagnostic Divisionreportable segmentsegment profit2018-01-01 → 2018-12-31−¥170m
Pharmaceutical Divisionreportable segmentrevenue2018-01-01 → 2018-12-31¥153m
Pharmaceutical Divisionreportable segmentrevenue external2018-01-01 → 2018-12-31¥153m
Pharmaceutical Divisionreportable segmentsegment profit2018-01-01 → 2018-12-31−¥485m
Total Of Reportable Segments And Otherssegment totalrevenue2018-01-01 → 2018-12-31¥169m
Total Of Reportable Segments And Otherssegment totalrevenue external2018-01-01 → 2018-12-31¥169m
Total Of Reportable Segments And Otherssegment totalsegment profit2018-01-01 → 2018-12-31−¥654m
Reconciling Itemsreconcilingdepreciation2017-01-01 → 2017-12-31¥1m
Reconciling Itemsreconcilingsegment profit2017-01-01 → 2017-12-31−¥537m
Diagnostic Divisionreportable segmentrevenue2017-01-01 → 2017-12-31¥33m
Diagnostic Divisionreportable segmentrevenue external2017-01-01 → 2017-12-31¥33m
Diagnostic Divisionreportable segmentsegment profit2017-01-01 → 2017-12-31−¥104m
Pharmaceutical Divisionreportable segmentrevenue2017-01-01 → 2017-12-31¥197m
Pharmaceutical Divisionreportable segmentrevenue external2017-01-01 → 2017-12-31¥197m
Pharmaceutical Divisionreportable segmentsegment profit2017-01-01 → 2017-12-31−¥438m
Total Of Reportable Segments And Otherssegment totalrevenue2017-01-01 → 2017-12-31¥229m
Total Of Reportable Segments And Otherssegment totalrevenue external2017-01-01 → 2017-12-31¥229m
Total Of Reportable Segments And Otherssegment totalsegment profit2017-01-01 → 2017-12-31−¥542m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 679
ItemContextValueUnit
Operating incomeCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000DiagnosticDivisionReportableSegmentsMember-169734000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember-654353000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember-593210000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember-1247563000JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000PharmaceuticalDivisionReportableSegmentsMember－JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000DiagnosticDivisionReportableSegmentsMember－JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember－JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember1709000JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember1709000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書(令和４年11月17日付け訂正報告書の添付インラインXBRL)
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2019-03-29
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第15期(自　平成30年１月１日　至　平成30年12月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)オンコリスバイオファーマ株式会社
Company name in english cover pageFilingDateInstantOncolys BioPharma Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　浦田　泰生
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都港区虎ノ門四丁目１番28号
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)03－5472－1578(代表)
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)取締役管理担当　　吉村　圭司
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都港区虎ノ門四丁目１番28号
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)03－5472－1578(代表)
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)取締役管理担当　　吉村　圭司
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE30058
Fund codeFilingDateInstant－
Security codeFilingDateInstant45880
Filer name in japaneseFilingDateInstant
Original text (Japanese)オンコリスバイオファーマ株式会社
Filer name in englishFilingDateInstantOncolys BioPharma Inc.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第三号様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstantfalse
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstant－
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstantcte
Current fiscal year start dateFilingDateInstant2018-01-01
Current period end dateFilingDateInstant2018-12-31
Type of current periodFilingDateInstantFY
Current fiscal year end dateFilingDateInstant2018-12-31
Previous fiscal year start dateFilingDateInstant2017-01-01
Comparative period end dateFilingDateInstant2017-12-31
Previous fiscal year end dateFilingDateInstant2017-12-31
Next fiscal year start dateFilingDateInstant－
End date of quarterly or semi annual period of next fiscal yearFilingDateInstant－
Amendment flagFilingDateInstanttrue
Identification of document subject to amendmentFilingDateInstantS100FIR2
Report amendment flagFilingDateInstanttrue
Xbrl amendment flagFilingDateInstantfalse

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2017-12-31pass rounding
balance sheet identitynon_consolidated 2018-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2016-12-31pass
statement vs summary · net assetsnon_consolidated 2017-12-31pass
statement vs summary · net assetsnon_consolidated 2018-12-31pass
statement vs summary · operating cash flownon_consolidated 2017-01-01/2017-12-31pass
statement vs summary · operating cash flownon_consolidated 2018-01-01/2018-12-31pass
statement vs summary · revenuenon_consolidated 2017-01-01/2017-12-31pass
statement vs summary · revenuenon_consolidated 2018-01-01/2018-12-31pass
statement vs summary · total assetsnon_consolidated 2017-12-31pass
statement vs summary · total assetsnon_consolidated 2018-12-31pass